JP2022513729A5 - - Google Patents

Info

Publication number
JP2022513729A5
JP2022513729A5 JP2021532041A JP2021532041A JP2022513729A5 JP 2022513729 A5 JP2022513729 A5 JP 2022513729A5 JP 2021532041 A JP2021532041 A JP 2021532041A JP 2021532041 A JP2021532041 A JP 2021532041A JP 2022513729 A5 JP2022513729 A5 JP 2022513729A5
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
sequence
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021532041A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513729A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/065212 external-priority patent/WO2020118295A1/en
Publication of JP2022513729A publication Critical patent/JP2022513729A/ja
Publication of JP2022513729A5 publication Critical patent/JP2022513729A5/ja
Priority to JP2024177850A priority Critical patent/JP2025016505A/ja
Withdrawn legal-status Critical Current

Links

JP2021532041A 2018-12-07 2019-12-09 ヒト化及び親和性成熟抗ceacam1抗体 Withdrawn JP2022513729A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024177850A JP2025016505A (ja) 2018-12-07 2024-10-10 ヒト化及び親和性成熟抗ceacam1抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862776877P 2018-12-07 2018-12-07
US62/776,877 2018-12-07
PCT/US2019/065212 WO2020118295A1 (en) 2018-12-07 2019-12-09 Humanized and affinity-matured anti-ceacam1 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024177850A Division JP2025016505A (ja) 2018-12-07 2024-10-10 ヒト化及び親和性成熟抗ceacam1抗体

Publications (2)

Publication Number Publication Date
JP2022513729A JP2022513729A (ja) 2022-02-09
JP2022513729A5 true JP2022513729A5 (cg-RX-API-DMAC7.html) 2022-12-19

Family

ID=70973892

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021532041A Withdrawn JP2022513729A (ja) 2018-12-07 2019-12-09 ヒト化及び親和性成熟抗ceacam1抗体
JP2024177850A Pending JP2025016505A (ja) 2018-12-07 2024-10-10 ヒト化及び親和性成熟抗ceacam1抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024177850A Pending JP2025016505A (ja) 2018-12-07 2024-10-10 ヒト化及び親和性成熟抗ceacam1抗体

Country Status (7)

Country Link
US (2) US12173066B2 (cg-RX-API-DMAC7.html)
EP (1) EP3906261A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022513729A (cg-RX-API-DMAC7.html)
CN (2) CN120209144A (cg-RX-API-DMAC7.html)
AU (1) AU2019393077B2 (cg-RX-API-DMAC7.html)
CA (1) CA3121580A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020118295A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3906261A4 (en) * 2018-12-07 2022-12-21 The Brigham And Women's Hospital, Inc. HUMANIZED AND AFFINITY MATURED ANTI-CEACAM1 ANTIBODIES
IT202100033002A1 (it) * 2021-12-29 2023-06-29 Diatheva S R L Anticorpi umani e loro usi
JP2025506405A (ja) * 2022-02-03 2025-03-11 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド ヒトceacam1に方向づけられた治療剤に対するコンパニオン診断
WO2023168326A2 (en) * 2022-03-03 2023-09-07 The Brigham And Women´S Hospital, Inc. Humanized and affinity-matured anti-ceacam1 antibodies and methods of use
CN121335923A (zh) * 2023-04-13 2026-01-13 苏州逻晟生物医药有限公司 Ceacam1靶向抗体及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2668874T3 (es) 2009-04-30 2018-05-22 Tel Hashomer Medical Research Infrastructure And Services Ltd. Anticuerpos anti-CEACAM1 y métodos de uso de los mismos
CA2800311A1 (en) * 2010-05-11 2011-11-17 Aveo Pharmaceuticals, Inc. Anti-fgfr2 antibodies
WO2013054320A1 (en) * 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
ES2753614T3 (es) * 2011-12-01 2020-04-13 Brigham & Womens Hospital Inc Anticuerpos recombinantes anti-CEACAM1 para terapia contra el cáncer
ES2980417T3 (es) * 2013-11-25 2024-10-01 Famewave Ltd Composiciones que comprenden anticuerpos anti-CEACAM1 y anti-PD para la terapia del cáncer
JP6805428B2 (ja) 2014-04-27 2021-01-06 フェイムウェイヴ リミテッド Ceacam1に対するヒト化抗体
WO2016120331A1 (de) 2015-01-28 2016-08-04 Karl Sebastian Lang Agonistische anti-cd66cd66 antikörper für die antiviralen therapie
US20180153986A1 (en) * 2015-04-24 2018-06-07 The Brigham And Women's Hospital, Inc. Interactions between ceacam and tim family members
NZ756585A (en) 2017-03-24 2022-09-30 Green Cross Corp Anti-ceacam1 antibody and use thereof
EP3906261A4 (en) * 2018-12-07 2022-12-21 The Brigham And Women's Hospital, Inc. HUMANIZED AND AFFINITY MATURED ANTI-CEACAM1 ANTIBODIES

Similar Documents

Publication Publication Date Title
JP7844558B2 (ja) リンパ球における阻害経路の中和
JP2017535257A5 (cg-RX-API-DMAC7.html)
JP2021534096A5 (cg-RX-API-DMAC7.html)
JP2022515318A5 (cg-RX-API-DMAC7.html)
JP2018523493A5 (cg-RX-API-DMAC7.html)
JP2019513725A5 (cg-RX-API-DMAC7.html)
JP2020510422A5 (cg-RX-API-DMAC7.html)
RU2018106452A (ru) Поливалетные и полиспецифичные gitr-связывающие слитые белки
JP2018532383A5 (cg-RX-API-DMAC7.html)
HRP20201928T1 (hr) Kombinirana terapija bispecifičnom antigen vezujućom molekulom koja aktivira t-stanice, za cd3 i folatni receptor 1 (folr1), i antagonistom vezivanja osi pd-1
JP2019524693A5 (cg-RX-API-DMAC7.html)
IL253462B (en) Cancer treatment with monoclonal antibodies against latency-associated peptide
JP2015163068A5 (cg-RX-API-DMAC7.html)
JP2016510002A5 (cg-RX-API-DMAC7.html)
JP2021533796A5 (cg-RX-API-DMAC7.html)
RU2018102803A (ru) Мультивалентные и мультиспецифические гибридные белки, связывающиеся с dr5
JP2018522888A5 (cg-RX-API-DMAC7.html)
JP2021517152A5 (cg-RX-API-DMAC7.html)
JP2021522347A5 (cg-RX-API-DMAC7.html)
JP2021511387A5 (cg-RX-API-DMAC7.html)
WO2023040940A1 (zh) Pvrig/tigit结合蛋白联合免疫检查点抑制剂用于治疗癌症
JP2023517794A5 (cg-RX-API-DMAC7.html)
JP2023509214A5 (cg-RX-API-DMAC7.html)
JP2020528936A5 (cg-RX-API-DMAC7.html)
CN112351794A (zh) 用于尿路上皮癌的免疫治疗方法